CPHI Webinar Series

Fragment-Based Oligonucleotide and Oligopeptide Synthesis

30th July, 2024
4pm CET / 10am EST
What will this webinar address?

In this webinar, you will learn how Asymchem is pioneering the integration of state-of-the-art technologies to create life-saving medications responsibly and sustainably, in accordance with environmental stewardship principles and healthcare needs. Through the comprehensive adoption of advanced methods such as biocatalysts and continuous processing, the company enhances operational efficiency, reduces costs, minimizes waste, and effectively mitigates risks in the production of small molecules, biologics, oligonucleotides, and oligopeptides. This commitment to technological innovation across all drug substance modalities distinguishes Asymchem from traditional CDMOs.

When you attend this webinar, you will:

  • Hear experts talk about Fragment-Based Oligonucleotide and Oligopeptide Synthesis
  • The integration of state-of-the-art technologies to create life-saving medications responsibly and sustainably
  • Walk away with insight into the future of drug substance modalities.
  • James Reidy
    Senior Conference Producer
    Pharma, Informa Markets

    James is an experienced events producer, who has developed and led multiple events across the life science industry for leading events organisations, while keeping the highest standards in terms of quality and delivery. Now at Informa Markets as Senior Content Producer, James oversees the content for CPHI North America and CPHI webinar series, helping in creating cutting edge sessions and providing guidance in creating interactive and educational talks.

    Charles Chase, PhD
    VP Technical Business Development
    Asymchem

    Charles Chase, PhD, currently holds the role as the Vice President of Technical Business Development at Asymchem. Before joining Asymchem, he served as Vice President of Pharmaceutical Development at Elicio Therapeutics and Senior Principal Scientist at Eisai Inc. With experience spanning over 20 years in Chemistry, Manufacturing, and Controls (CMC), he possesses a deep understanding of process research and development across various substances, including oligonucleotides, peptides, and complex small molecules like Halaven®. His expertise encompasses synthesis, route optimization, CMC/CDMO management, and navigating regulatory approval processes.

    This webinar is brought to you by

    Overview
    Fragment-Based Oligonucleotide and Oligopeptide Synthesis
    • 30th July, 2024
    • 4pm CET / 10am EST
    • 60 minutes
    • Free